Revenue

3 Months Ended

Mar. 31, 2022

Disaggregation Of Revenue [Abstract]

Revenue

11. Revenue

The following table provides information about disaggregated revenue by product mix and service (in thousands):

	Three Months Ended March 31,
	2022		2021
Product revenue:
ANNOVERA	$	8,510	$	8,750
IMVEXXY		6,969		7,012
BIJUVA		2,560		2,445
Prescription vitamin		875		1,425
Product revenue, net		18,914		19,632
License and service		419		234
Total revenue, net	$	19,333	$	19,866

We have entered into a license and supply agreement (the “Knight License Agreement”), with Knight Therapeutics, Inc. (“Knight”) pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. We also have entered into a licensing and supply agreement (the “Theramex License Agreement”) with Theramex HQ UK Limited (“Theramex”) pursuant to which we granted Theramex an exclusive license to commercialize IMVEXXY and BIJUVA for human use outside of the U.S., except for Canada and Israel.

BIJUVA sales through the Theramex License Agreement started in the third quarter of 2021, and we recorded BIJUVA sales of $0.7 million for the three months ended March 31, 2022. As of March 31, 2022, no BIJUVA sales have been made through the Knight License Agreement, and no IMVEXXY sales have been made through either of the licensing agreements.